InvestorsHub Logo
Followers 26
Posts 6459
Boards Moderated 4
Alias Born 03/20/2017

Re: None

Sunday, 11/04/2018 2:41:16 PM

Sunday, November 04, 2018 2:41:16 PM

Post# of 10580
Possibly the CANNABIS DEAL of this year - it`s intresting times ahead.

QUEENSLAND BAUXITE LIMITED (TO BE RENAMED CANN GLOBAL LIMITED by mid november) ACN 124 873 507 SECOND SUPPLEMENTARY PROSPECTUS
1. IMPORTANT INFORMATION This is a second supplementary prospectus (Second Supplementary Prospectus) which is intended to be read with the prospectus dated 27 September 2018 and the initial supplementary prospectus dated 17 October 2018 (First Supplementary Prospectus) (the prospectus and the First Supplementary Prospectus collectively referred to in this document as the Prospectus) issued by Queensland Bauxite Limited (to be renamed Cann Global Limited) (ACN 124 873 507) (Company).


https://www.queenslandbauxite.com/

This Second Supplementary Prospectus dated 31 October 2018 was lodged with the ASIC on that date. The ASIC, ASX and their respective officers take no responsibility for the contents of this Second Supplementary Prospectus. This Second Supplementary Prospectus should be read together with the Prospectus. Other than as set out below, all details in relation to the Prospectus remain unchanged. Terms and abbreviations defined in the Prospectus have the same meaning in this Second Supplementary Prospectus. If there is a conflict between the Prospectus and this Second Supplementary Prospectus, this Second Supplementary Prospectus will prevail. This Second Supplementary Prospectus will be issued with the Prospectus as an electronic prospectus and may be accessed on the Company’s website at www.queenslandbauxite.com.


This is an important document and should be read in its entirety. If you do not understand it, you should consult your professional advisers without delay. 2. MATERIAL CONTRACTS
Since the Company lodged its Prospectus, Medcan has entered into the following material contracts or arrangements with third parties: (a) Bonify Agreement
Medcan has entered into a strategic collaboration agreement with Canadian based Bonify Holdings Corporation (Bonify). For a summary of the key terms of this agreement, please refer to the copy of the Company’s ASX announcement dated 24 October 2018, attached as Annexure A. (b) Pharmocann Agreement
Medcan has entered into a memorandum of understanding with Israeli based medicinal cannabis company Pharmocann Ltd (Pharmocann). For a summary of the key terms of this agreement, please refer to the copy of the Company’s ASX announcement dated 18 October 2018, attached as Annexure B.


3. ADDITIONAL INFORMATION ON QBL’S BUSINESS MODEL
Operation within the medicinal cannabis and hemp industries is subject to a stringent licencing regime, with a number of licences, approvals or permits required in order to
Sholom Feldman Director 31 October 2018
This Second Supplementary Prospectus is intended to be read with the prospectus dated 27 September 2018 and the initial supplementary prospectus dated 17 October 2018 issued by Queensland Bauxite Limited (to be renamed Cann Global Limited) (ACN 124 873 507)

2
conduct business activities within these industries at various stages of business operation.
A key dependency of QBL’s current business model, and its proposed business model following completion of the Acquisitions, is the Company Group’s ability to retain its existing licences and apply for the additional licences, permits or approvals which will become required as the business of the Company Group develops and reaches new stages of operation. This will involve the constant monitoring of applicable licencing requirements and implementation of strategies to ensure such licences, permits and approvals are renewed or applied for at the necessary stages.


Medcan and MCL currently have, or have interests in, a range of licences, permits and approvals which are required under applicable legislation to operate their respective medicinal cannabis and hemp businesses. The table below sets out these existing licences: Type of licence Purpose of licence Party holding or having access to the licence Date licence is due for renewal Medicinal Cannabis products
OCD Cultivation and Production Licence MC013/171
Cultivation of cannabis plants and production of cannabis or cannabis resin, subject to it obtaining a medicinal cannabis permit
Medcan 30 June 2019
Import Licence 18207381
Import of various cannabis products subject to the issue of a specific permit
Medcan 31 December 2018
Export Licence 18207391
Export of various cannabis products subject to the issue of a specific permit
Medcan 31 December 2018
ODC Manufacturing Licence1,2 ML015/18
Manufacture of cannabis and cannabis resin and related activities, subject to it obtaining a manufacture permit
Medcan 8 October 2019
Department of Agriculture and Water Resources Permit2 0002005875
Importation of plant materials, specifically cannabis seeds
Medcan 25 July 2019
Qld Health Approval AG007354718
Obtaining and possession and use of cannabis seeds.

https://hotcopper.com.au/threads/ann-cover-note-and-second-supplementary-prospectus.4517055/#.W9nyLvZFzIV


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.